Table 4.
Subsequent therapies after nivolumab
| Subsequent therapies after nivolumab | Nivolumab treatment duration | ||
|---|---|---|---|
| <2 y | 2 y | >2 y | |
| n = 25 | n = 1 | n = 1 | |
| Carboplatin/ gemcitabine or paclitaxel/ ± bevacizumab | 6 (24.0) | — | — |
| Paclitaxel/ bevacizumab | 3 (12.0) | — | — |
| Pemetrexed/ bevacizumab | 1 (4.0) | — | — |
| Paclitaxel or gemcitabine or pemetrexed | 4 (16.0) | — | — |
| Docetaxel | 3 (12.0) | — | — |
| Rechallenge nivolumab | 2 (8.0) | 1 (100) | — |
| Targeted therapy a | 3 (12.0) | — | — |
| Other | 1 (4.0) | — | — |
| Missing data | 2 (8.0) | — | 1 (100) |
Results are expressed as n (%).
a
erlotinib (n = 2), afatinib (n = 1).